[Role of alkaline phosphatase Regan isoenzyme in prognosis of patients with osteosarcoma].
The presence of Regan isoenzyme (the heat stable fraction of alkaline phosphatase) in serum of patients with osteosarcoma has been proposed as a prognostic factor indicating the metastatic evolution of the disease. This work reports on 9 patients with osteosarcoma. In 4 of them Regan isoenzyme was present 4, 6, 12, and 16 months before clinical-instrumental evidence of lung metastases. These results further support the significance of this isoenzyme as a marker of relapse in an early subclinical stage.
Tucci
A
A
I Divisione di Ortopedia e Traumatologia, Ospedale Santobono, Napoli.
Saviano
C
C
Del Prete
S
S
D000293:Adolescent; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood*; D001859:Bone Neoplasms / Q000175:diagnosis / Q000201:enzymology*; D004796:Clinical Enzyme Tests; D005260:Female; D058851:GPI-Linked Proteins; D006801:Humans; D007527:Isoenzymes / Q000097:blood*; D008297:Male; D012516:Osteosarcoma / Q000175:diagnosis / Q000201:enzymology*
D058851:GPI-Linked Proteins; D007527:Isoenzymes; D000469:Alkaline Phosphatase; C019839:alkaline phosphatase, placental
Il ruolo dell'isoenzima di Regan della fosfatasi alcalina nella prognosi dei pazienti affetti da osteosarcoma.